Table 1.
Baseline demographic, clinical, electrocardiographic, and AF subtype of the study population
| Baseline patient characteristics | N = 68 patients |
|---|---|
| Demographics | |
| Age (years) | 64.3 (±10.5) |
| Male (%) | 75% |
| Body mass index (kg/m2) | 27.8 (±5.7) |
| CHA2DS2-VASc score | 1.9 (±1.4) |
| Echocardiography parameters | |
| LA size (mm) | 45.5 (± 9.3) |
| LVEF, n (%) | 58.9 (7.7) |
| Past medical history | |
| Hypertension, n (%) | 30 (44) |
| Diabetes, n (%) | 8 (12) |
| Dyslipidaemia, n (%) | 8 (12) |
| Congestive heart failure, n (%) | 14 (21) |
| Coronary artery disease, n (%) | 6 (9) |
| Stroke/TIA, n (%) | 6 (9) |
| Sleep apnoea, n (%) | 8 (12) |
| Chronic renal failure, n (%) | 1 (1.4) |
| Chronic obstructive pulmonary disease, n (%) | 1 (1.4) |
| Medications | |
| Vitamin K antagonist, n (%) | 2 (3) |
| DOAC, n (%) | 66 (97) |
| Anti-arrhythmic drug use, n (%) | 38 (56) |
| Indication for ablation | |
| Paroxysmal atrial fibrillation, n (%) | 24 (35) |
| Persistent atrial fibrillation, n (%) | 20 (29) |
| Long-standing persistent AF, n (%) | 24 (35) |
Values are expressed as mean (SD) or percentage.
LA size, left atrial size; LVEF, left ventricular ejection fraction; TIA, transient ischaemic attack; DOAC, direct oral anticoagulant; AF, atrial fibrillation.